The drug works by blocking the activity of key receptors important for the development of blood vessels that supply tumors, as well as receptors critical for tumor survival.
"At the completion of a Palladia clinical study, approximately 60 percent of the dogs had their tumors disappear, shrink or stop growing," said Cheryl London, DVM, PhD, board-certified medical oncologist and associate professor at The Ohio State University College of Veterinary Medicine. "Also, we determined that dogs whose tumors responded to Palladia experienced an improved quality of life."
Dr. London has worked with Pfizer Animal Health's Veterinary Medicine Research & Development in developing Palladia since 2000.
Now, the above approx 60% is factual (per stats below) but I take away from that statement a more positive perception than it possibly deserves after viewing the actual clinical results below. Hopefully Bioniche is learning from their competition. Worried they would stop at the CR % below...as they now seem to take the other extreme (only half kidding). Not suggesting overstating. Footnotes work.
Anyways, found this of interest and thought I would share. But more work than thought! Enjoy the evening which I will now start. rg
Here are Palladia's clinical trial results:
Complete Response (CR): 8.1%
Partial Response (PR): 29.1%
Stable Disease (SD): 20.9% CR + PR + SD = 58.1%
Progressive Disease (PD): 32.6%
D/C for Adverse Event: 3.5%
D/C due to owner's request 5.8%
Total: 100%
Number of dogs: 86
Study length: 6 week results (but over a two year period to achieve)....I believe.
P.S... No idea of Palladia's revenue figure...if anyone has it appreciate if you share. Seeing some pricing info but haven't had time to figure out total treatment cost as based on weight of dog, multiple/ different pills, etc.
P.P.S....really like what I am seeing so far for new revenue potential for Bioniche! Execution will be critical....hopefully they have their pups in a row!